Experts Weigh In On Zocor "Pharmacy Status" In U.K., Prospects For U.S. Statin Switch
This article was originally published in The Pink Sheet Daily
Executive Summary
Four experts in cardiovascular medicine participated in interviews with "The Tan Sheet" to discuss the U.K.'s decision to switch Merck's cholesterol-lowering drug simvastatin 10 mg behind-the-counter.
You may also be interested in...
U.K.’s NICE Endorses Low-Cost Statins To Treat Cardiovascular Disease
Recommendations from the cost-effectiveness agency could make 3.3 mil. people in the U.K. eligible for statin therapy.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.